SCHEMBL129541

SCHEMBL129541

[CH2]CCC(C)(C)OC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11136706 0.85 ALDH1A1 (0.35)
SCHEMBL386550 0.82
SCHEMBL386485 0.80 ALDH1A1 (0.39)
SCHEMBL1908110 0.79 ALDH1A1 (0.56)
SCHEMBL384233 0.78 ALDH1A1 (0.38)
SCHEMBL20820006 0.78 ALDH1A1 (0.38)
SCHEMBL64765 0.75
SCHEMBL127065 0.73
SCHEMBL2591293 0.73
Methoxymethane SCHEMBL1476203 0.73 ALDH1A1 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116854624-A Process for producing optically active pyrrolidine compound 田边三菱制药株式会社 2023-10-10 CN disclosed
US-11746099-B2 Method for producing optically active pyrrolidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-09-05 US disclosed
EP-3578545-B1 METHOD FOR PRODUCING OPTICALLY ACTIVE PYRROLIDINE COMPOUNDS MITSUBISHI TANABE PHARMA CORP (JP) 2023-07-26 EP disclosed
CN-110234626-B Process for producing optically active pyrrolidine compound 田边三菱制药株式会社 2023-07-21 CN disclosed
US-20230226034-A1 PROPHYLACTIC OR THERAPEUTIC AGENT FOR PHOTODERMATOSIS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-07-20 US disclosed
EP-4166139-A1 PREVENTIVE OR THERAPEUTIC AGENT FOR ACTINIC SKIN DISEASE Mitsubishi Tanabe Pharma Corporation (JP) 2023-04-19 EP disclosed
CN-115768428-A Prophylactic or therapeutic agent for photodermatosis 田边三菱制药株式会社 2023-03-07 CN disclosed
US-20220119364-A2 METHOD FOR PRODUCING OPTICALLY ACTIVE PYRROLIDINE COMPOUNDS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2022-04-21 US disclosed
US-20210300896-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE PYRROLIDINE COMPOUNDS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2021-09-30 US disclosed
CN-112194649-A Pyrrolidine compounds and their use as melanocortin receptor agonists 田边三菱制药株式会社 2021-01-08 CN disclosed
EP-0369335-B1 2-Aminodecaline derivatives and their use BASF AG (DE) 1994-02-23 EP disclosed
US-5051409-A Fungicides BASF AKTIENGESELLSCHAFT (DE) 1991-09-24 US disclosed
EP-0369335-A2 2-Aminodecaline derivatives and their use BASF Aktiengesellschaft (DE) 1990-05-23 EP disclosed
EP-0030109-B1 PROCESS FOR PRODUCING ISOPRENE KURARAY CO., LTD. (JP) 1983-10-05 EP disclosed
US-4381416-A Process for producing isoprene KURARAY CO., LTD. (JP) 1983-04-26 US disclosed
EP-0030109-A1 Process for producing isoprene KURARAY CO., LTD. (JP) 1981-06-10 EP disclosed
EP-0004335-A2 Prostacyclin analogs, process and intermediates for their preparation and their use as medicines HOECHST AKTIENGESELLSCHAFT (DE) 1979-10-03 EP disclosed
US-4026910-A Oxidation process using nickel peroxide oxidizing agents HOFFMANN-LA ROCHE INC. (US) 1977-05-31 US disclosed
US-3994936-A Catalytic rearrangement HOFFMANN-LA ROCHE INC. (US) 1976-11-30 US disclosed
US-3981896-A CONVERSION OF ACETYLENIC ALCOHOLS TO ALDEHYDES AND KETONES HOFFMANN-LA ROCHE INC. (US) 1976-09-21 US disclosed